Table 1 Demographic and clinical characteristics of patients treated with immune checkpoint inhibitors
Characteristics | All (n = 424) | Newly diagnosed CVD (n = 62) | No CVD (n = 362) | P |
|---|---|---|---|---|
Age (year) | 62 ± 13.1 | 64.3 ± 10.2 | 62.1 ± 13.5 | 0.135 |
Sex | 0.924 | |||
Women | 155 (36.6%) | 23 (37.1%) | 132 (36.5%) | |
Men | 269 (63.4%) | 39 (62.9%) | 230 (63.5%) | |
Race/Ethnicity | 0.772 | |||
White (non-Hispanic) | 363 (85.6%) | 55 (88.7%) | 308 (85.0%) | |
Black (non-Hispanic) | 32 (7.6%) | 4 (6.5%) | 28 (7.8%) | |
Hispanic | 16 (3.8%) | 1 (1.6%) | 15 (4.2%) | |
Other | 13 (3.1%) | 2 (3.2%) | 11 (3.1%) | |
Primary cancer diagnosis | 0.163 | |||
Lung cancer | 126 (29.7%) | 20 (32.3%) | 106 (29.3%) | |
Melanoma | 72 (17.0%) | 16 (25.8%) | 56 (15.5%) | |
Kidney cancer | 54 (12.7%) | 7 (11.3%) | 47 (13.0%) | |
Head and neck cancer | 45 (10.6%) | 6 (9.7%) | 39 (10.8%) | |
Urothelial carcinoma | 34 (8.0%) | 6 (9.7%) | 28 (7.7%) | |
Colorectal cancer | 19 (4.5%) | 4 (6.5%) | 15 (4.1%) | |
Gastrointestinal cancers (other) | 8 (1.9) | 1 (1.6%) | 7 (1.9%) | |
Hodgkin Lymphoma | 7 (1.6%) | 0 | 7 (1.9%) | |
Other cancer | 59 (13.9%) | 2 (3.2%) | 57 (15.8%) | |
Cardiovascular risk factors | ||||
Hypertension | 210 (49.5%) | 36 (58.1%) | 174 (48.1%) | 0.146 |
Ischemic heart disease | 54 (12.7%) | 9 (14.5%) | 45 (12.4%) | 0.649 |
Hyperlipidemia | 128 (30.2%) | 24 (38.7%) | 104 (28.7%) | 0.114 |
Diabetes | 76 (17.9%) | 14 (22.6%) | 62 (17.1%) | 0.301 |
Other cancer medications | ||||
Doxorubicin | 14 (3.3%) | 3 (4.8%) | 11 (3.0%) | 0.464 |
Carboplatin | 114 (26.9%) | 18 (29.0%) | 96 (26.5%) | 0.68 |
Paclitaxel | 88 (20.8%) | 15 (24.2%) | 73 (20.2%) | 0.47 |
Cyclophosphamide | 4 (0.9%) | 1 (1.6%) | 3 (0.8%) | 0.555 |